It has shown that the sialyl-T antigen is not only expressed in normal cells but is also abnormally expressed in most human tumor cells and precancerous lesions. Therefore, the development of sialyl-T antigen inhibitors interferes with the biosynthesis as well as the expression process of sialyl-T antigens, which is important for human tumor and cancer research.
At CD BioGlyco, we provide sialyl-T antigen inhibitor development services that include but are not limited to:
In addition, we offer in vivo and in vitro testing in animals, as well as techniques such as attrition cytometry to detect the inhibitory effects of sialyl-T antibodies and sialyl-T antigen inhibitors, among other bioactivities.
Fig.1 Development process of sialyl-T antigen inhibitors. (CD BioGlyco)
Fig.2 (A) Structures of the reporter probes used for biotinylation 3 and 4. (B) Western blot analysis of chemoenzymatic labeling of breast cancer MCF7 and colon cancer HT29 cells. (Wen, et al., 2018)
CD BioGlyco is dedicated to Glycosylation Inhibitor Development Services, and we offer many types of inhibitor production services in this area. We hope to be your right hand in glycobiology. If you are interested in our services, please feel free to contact us.